University of Houston College of Pharmacy, 1441 Moursund St., Houston, TX, 77030, USA,
Curr Atheroscler Rep. 2015 Jan;17(1):471. doi: 10.1007/s11883-014-0471-8.
Cardiovascular disease is prevalent and costly. Interventions and therapies that reduce morbidity and mortality associated with cardiovascular disease could have an enormous impact on clinical and economic outcomes. Statins reduce atherosclerotic cardiovascular disease-related morbidity and mortality; however, adherence to statins is less than optimal. It is important for clinicians as well as health plan managers to be aware of the patient- and insurance plan-specific factors that have been shown to influence adherence. Perceived statin-related side effects may also decrease adherence. Statin-related myalgia may be difficult to distinguish from myalgia caused by other conditions, and statin therapy may be discontinued unnecessarily in patients who would otherwise benefit. It is imperative that clinicians work closely with patients to improve adherence to statin therapy and be knowledgable in managing potential statin-related side effects.
心血管疾病普遍存在且代价高昂。减少与心血管疾病相关的发病率和死亡率的干预措施和治疗方法可能对临床和经济结果产生巨大影响。他汀类药物可降低动脉粥样硬化性心血管疾病相关的发病率和死亡率；然而，他汀类药物的依从性并不理想。了解已证明会影响依从性的患者和保险计划特定因素，这对临床医生和健康计划管理者都很重要。患者可能会认为他汀类药物相关的副作用会降低其治疗的依从性。他汀类药物相关的肌痛可能难以与其他疾病引起的肌痛区分，否则可能会不必要地停止他汀类药物治疗，而实际上这些患者会从中受益。临床医生必须与患者密切合作，提高他汀类药物治疗的依从性，并了解管理潜在他汀类药物相关副作用的知识。
